Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable clinical and endoscopic remission through 92 weeks in adults with moderately to ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

I think the most important thing when you think about differentiating patients with ulcerative colitis from Crohn’s disease is that ulcerative colitis, by definition, starts in the rectum and ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

In these videos, Sushila Dulal, MD, associate professor of medicine at the University Chicago of Medicine, discusses the latest treatments, state of the pipeline and unmet needs for patients with ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

This hideous disease causes the body's nervous system to shut down, slowly paralysing the patient until they are unable to breathe. Tragically, there is no cure or treatment. As the cases piled up ...

Expert Rev Gastroenterol Hepatol. 2010;4(2):167-180. Expert Rev Gastroenterol Hepatol. 2010;4(2):167-180. © 2010 Expert Reviews Ltd. Cite this: What is the Optimal ...